<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01879332</url>
  </required_header>
  <id_info>
    <org_study_id>BIA-2093-118</org_study_id>
    <nct_id>NCT01879332</nct_id>
  </id_info>
  <brief_title>A Sequential Multiple Ascending Dose Study of the Safety and Pharmacokinetics of Eslicarbazepine Acetate in Adult Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Sequential Multiple Ascending Dose Study of the Safety and Pharmacokinetics of Eslicarbazepine Acetate in Adult Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bial - Portela C S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bial - Portela C S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, double-blind, placebo-controlled, sequential multiple ascending dose study to
      determine a maximum tolerated dose
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was designed as a randomized, double-blind, placebo-controlled, sequential
      multiple ascending dose study to assess the safety and pharmacokinetics of supratherapeutic
      doses of eslicarbazepine acetate in 32 healthy adult male and female subjects, with 8
      subjects per treatment group. In each study group, subjects were to receive single doses of
      eslicarbazepine acetate or placebo once daily for 5 days.

      A series of screening evaluations was performed within a 21-day period prior to the first
      dose of study medication in order to determine the eligibility of prospective study
      participants for the trial. Eligible subjects reported to the clinic on Day -1 prior to study
      medication administration and remained in the clinic until clinic discharge on Day 7. Plasma
      and urine samples were collected throughout the study to determine the pharmacokinetics of
      eslicarbazepine acetate and its metabolites.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events Reported</measure>
    <time_frame>2 days</time_frame>
    <description>Safety was evaluated through the recording and monitoring of adverse events</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo tablets for oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIA 2-093 3000 mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in Cohort 2 received a dose of 3000 mg once daily (5 x 600 mg eslicarbazepine acetate tablets)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIA 2-093 3600 mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in Cohort 1 received a dose of 3600 mg once daily (6 x 600 mg eslicarbazepine acetate tablets)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo tablets for oral administration</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>sugar pills</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIA 2-093 3000 mg once daily</intervention_name>
    <description>Eslicarbazepine acetate 600 mg tablets for oral administration</description>
    <arm_group_label>BIA 2-093 3000 mg once daily</arm_group_label>
    <other_name>eslicarbazepine acetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIA 2-093 3600 mg once daily</intervention_name>
    <description>Eslicarbazepine acetate 600 mg tablets for oral administration</description>
    <arm_group_label>BIA 2-093 3600 mg once daily</arm_group_label>
    <other_name>Eslicarbazepine acetate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female 18 to 45 years of age. Women were required to be postmenopausal
             (more than 12 months since last period); surgically sterile (hysterectomy or tubal
             ligation at least 6 months prior to enrollment); using an intrauterine device; or
             double barrier (i.e. diaphragm or spermicide plus male condom) non-hormonal
             contraceptive therapy for the duration of the trial. Female subjects were required to
             have a negative pregnancy test at screening and upon check-in to the study facility.

          -  BMI within the range of 18-30 kg/m2.

          -  Ability to communicate effectively with the study personnel.

          -  No significant disease or abnormal laboratory values as determined by medical history,
             physical examination or laboratory evaluations, conducted at the screening visit and
             on admission to the clinic.

          -  Normal 12-lead electrocardiogram, without any clinically significant abnormalities of
             rate, rhythm or conduction.

          -  Nonsmokers defined as not having smoked in the past 6 months.

          -  Subjects were to be adequately informed of the nature and risks of the study and were
             required to provide written informed consent prior to study entry.

        Exclusion Criteria:

          -  Known hypersensitivity or allergy to eslicarbazepine acetate or related compounds such
             as carbamazepine, oxcarbazepine, or licarbazepine.

          -  Women who were pregnant or breast feeding.

          -  Any disease or condition (medical or surgical) which, in the opinion of the
             investigator, had the potential to compromise the hematologic, cardiovascular,
             pulmonary, renal, gastrointestinal, hepatic, or central nervous system; or other
             conditions that could interfere with the absorption, distribution, metabolism or
             excretion of study drug, or would place the subject at increased risk.

          -  A sustained supine systolic blood pressure &gt; 140 mmHg or &lt;100mmHg or a diastolic blood
             pressure &gt; 95 mmHg at screening or baseline.

          -  A resting ECG heart rate of &lt;50 bpm or &gt;100 bpm.

          -  An abnormal screening ECG indicating a second- or third-degree AV block, or one or
             more of the following: QRS &gt; 110 milliseconds (msec), QTc (Fridericia correction) &gt;
             450 msec, PR interval &gt; 240 msec. Any rhythm other than sinus rhythm, which was
             interpreted by the Investigator to be clinically significant.

          -  The presence of abnormal laboratory values which were considered clinically
             significant.

          -  Positive screen for Hepatitis B (HbsAg, Hepatitis B Surface Antigen), Hepatitis C
             (anti HCV, Hepatitis C Antibody), or HIV (anti-HIV 1 or 2).

          -  Receipt of an investigational drug within a period of 30 days prior to enrollment in
             the study.

          -  Receipt of any drug therapy, including hormonal contraceptives, within 2 weeks prior
             to administration of the first dose of any study-related treatment. This exclusion was
             extended to 4 weeks for any drugs known to induce or inhibit hepatic drug metabolism.

          -  Consumption of alcohol within 48 hours prior to dose administration or during any
             in-patient period.

          -  A positive urine drug screen including ethanol, cocaine, THC, barbiturates,
             amphetamines, benzodiazepines, and opiates.

          -  Any history of alcohol abuse, illicit drug use, significant mental illness, physical
             dependence to any opioid, or any history of drug abuse or addiction.

          -  A history of difficulty with donating blood.

          -  Donation of blood or blood products within 45 days prior to enrollment.

          -  Subjects with, or with a history of, additional risk factors for Torsades de Points
             (e.g., heart failure, hypokalemia), or a family history of long QT syndrome or family
             history of sudden death.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Comprehensive Phase OneTM</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2013</study_first_submitted>
  <study_first_submitted_qc>June 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2013</study_first_posted>
  <results_first_submitted>November 28, 2014</results_first_submitted>
  <results_first_submitted_qc>December 17, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 19, 2014</results_first_posted>
  <last_update_submitted>December 17, 2014</last_update_submitted>
  <last_update_submitted_qc>December 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anticonvulsant</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eslicarbazepine acetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>BIA 2-093 3000 mg Once Daily</title>
          <description>Subjects in Cohort 2 received a dose of 3000 mg once daily (5 x 600 mg eslicarbazepine acetate tablets)
BIA 2-093 3000 mg once daily: Eslicarbazepine acetate 600 mg tablets for oral administration</description>
        </group>
        <group group_id="P2">
          <title>BIA 2-093 3600 mg Once Daily</title>
          <description>Subjects in Cohort 1 received a dose of 3600 mg once daily (6 x 600 mg eslicarbazepine acetate tablets)
BIA 2-093 3600 mg once daily: Eslicarbazepine acetate 600 mg tablets for oral administration</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Matching placebo tablets for oral administration
Placebo: Matching placebo tablets for oral administration</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Matching placebo tablets for oral administration
Placebo: Matching placebo tablets for oral administration</description>
        </group>
        <group group_id="B2">
          <title>BIA 2-093 3000 mg Once Daily</title>
          <description>Subjects in Cohort 2 received a dose of 3000 mg once daily (5 x 600 mg eslicarbazepine acetate tablets)
BIA 2-093 3000 mg once daily: Eslicarbazepine acetate 600 mg tablets for oral administration</description>
        </group>
        <group group_id="B3">
          <title>BIA 2-093 3600 mg Once Daily</title>
          <description>Subjects in Cohort 1 received a dose of 3600 mg once daily (6 x 600 mg eslicarbazepine acetate tablets)
BIA 2-093 3600 mg once daily: Eslicarbazepine acetate 600 mg tablets for oral administration</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Adverse Events Reported</title>
        <description>Safety was evaluated through the recording and monitoring of adverse events</description>
        <time_frame>2 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BIA 2-093 3000 mg Once Daily</title>
            <description>Subjects in Cohort 2 received a dose of 3000 mg once daily (5 x 600 mg eslicarbazepine acetate tablets)
BIA 2-093 3000 mg once daily: Eslicarbazepine acetate 600 mg tablets for oral administration</description>
          </group>
          <group group_id="O2">
            <title>BIA 2-093 3600 mg Once Daily</title>
            <description>Subjects in Cohort 1 received a dose of 3600 mg once daily (6 x 600 mg eslicarbazepine acetate tablets)
BIA 2-093 3600 mg once daily: Eslicarbazepine acetate 600 mg tablets for oral administration</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo tablets for oral administration
Placebo: Matching placebo tablets for oral administration</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events Reported</title>
          <description>Safety was evaluated through the recording and monitoring of adverse events</description>
          <units>Number of adverse events reported</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nervous system AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General and Administration Site Conditions AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eye AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin and Subcutaneous Tissue AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>BIA 2-093 3000 mg Once Daily</title>
          <description>Subjects in Cohort 2 received a dose of 3000 mg once daily (5 x 600 mg eslicarbazepine acetate tablets)
BIA 2-093 3000 mg once daily: Eslicarbazepine acetate 600 mg tablets for oral administration</description>
        </group>
        <group group_id="E2">
          <title>BIA 2-093 3600 mg Once Daily</title>
          <description>Subjects in Cohort 1 received a dose of 3600 mg once daily (6 x 600 mg eslicarbazepine acetate tablets)
BIA 2-093 3600 mg once daily: Eslicarbazepine acetate 600 mg tablets for oral administration</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Matching placebo tablets for oral administration
Placebo: Matching placebo tablets for oral administration</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (8.1)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia Oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Paraesthesia Oral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Clinical Research</name_or_title>
      <organization>Bial – Portela &amp; Cª, S.A.</organization>
      <phone>+351 229 866 100</phone>
      <email>jose.rocha@bial.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

